Global Diabetic Neuropathy Market Size study, by Types of Disorder (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy), and by Regional Forecasts 2018-2025

August 2018 | 120 pages | ID: G22DE04BE66EN
Bizwit Research & Consulting LLP

Abstracts

Global Diabetic Neuropathy Market to reach USD 8460.3 million by 2025.

Global Diabetic Neuropathy Market valued approximately USD 4680 million in 2016 is anticipated to grow with a healthy growth rate of more than 6.80% over the forecast period 2017-2025. The growth of this market primarily driven by the ever-growing pool of geriatric population with diabetes. The rise in availability of suitable treatment options and the growing awareness on PDN catalyzes the demand for PDN drugs. With only four drugs currently approved for the management of PDN (Lyrica, Cymbalta, Nucynta and Qutenza), there arises a huge opportunity for new and emerging market players with potential pipeline portfolio. Of the marketed products analyzed, Lyrica accounted for a maximum market share in 2017 and will continue similar trend through 2026.

The recent approval of Lyrica's control release formulation in October 2017 further augments its market growth. The PDN drugs market observes a presence of strong pipeline portfolio, which would facilitate the overall growth during the forecast period from 2018 to 2026. Varoomed Co. Ltd.'s VM202 currently in phase III is the only gene therapy developed with disease modifying properties. However, the higher pricing of gene therapy could hamper the growth of VM202 in future.

With diabetes being a global concern, PDN drugs market comprises a worldwide outreach. In 2017, North America dominated the market and expected to maintain its position throughout the forecast period. Availability of approved drugs and the presence of extensive diabetic patient pool contributed to the overall market growth. Asia Pacific exhibited fastest CAGR during the forecast period due to the growing awareness of PDN and the rise in healthcare expenditure.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type of Disorder:

• Peripheral Neuropathy
• Autonomic Neuropathy
• Proximal Neuropathy
• Focal Neuropathy

By Regions:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• Asia Pacific
• China
• India
• Japan
• Latin America
• Brazil
• Mexico
• Rest of the World

Furthermore, years considered for the study are as follows:

• Historical year – 2015, 2016
• Base year – 2017
• Forecast period – 2018 to 2025

The industry is seeming to be fairly competitive. Some of the leading market players include Pfizer, Inc, Johnson & Johnson, Boehringer Ingelheim GmbH., NeuroMetrix, Inc., Eli Lilly and Company, Astellas Pharma Inc, GlaxoSmithKline plc., Lupin Limited, Depomed, Inc., Glenmark Pharmaceuticals Ltd., Arbor Pharmaceuticals, LLC and so on. Acquisitions and effective mergers are some of the strategies adopted by the key manufacturers. New product launches and continuous technological innovations are the key strategies adopted by the major players.

Target Audience of the Global Diabetic Neuropathy Market in Market Study:

• Key Consulting Companies & Advisors
• Large, medium-sized, and small enterprises
• Venture capitalists
• Value-Added Resellers (VARs)
• Third-party knowledge providers
• Investment bankers
• Investors

Contents

CHAPTER 1. GLOBAL DIABETIC NEUROPATHY MARKET DEFINITION AND SCOPE

1.1. Research Objective
1.2. Market Definition
1.3. Scope of The Study
1.4. Years Considered for The Study
1.5. Currency Conversion Rates
1.6. Report Limitation

CHAPTER 2. RESEARCH METHODOLOGY

2.1. Research Process
  2.1.1. Data Mining
  2.1.2. Analysis
  2.1.3. Market Estimation
  2.1.4. Validation
  2.1.5. Publishing
2.2. Research Assumption

CHAPTER 3. EXECUTIVE SUMMARY

3.1. Global & Segmental Market Estimates & Forecasts, 2015-2025 (USD Billion)
3.2. Key Trends

CHAPTER 4. GLOBAL DIABETIC NEUROPATHY MARKET DYNAMICS

4.1. Growth Prospects
  4.1.1. Drivers
  4.1.2. Restraints
  4.1.3. Opportunities
4.2. Industry Analysis
  4.2.1. Porter’s 5 Force Model
  4.2.2. PEST Analysis
  4.2.3. Value Chain Analysis
4.3. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL DIABETIC NEUROPATHY MARKET, BY TYPE OF DISORDER

5.1. Market Snapshot
5.2. Market Performance - Potential Model
5.3. Global Diabetic Neuropathy Market, Sub Segment Analysis
  5.3.1. Peripheral Neuropathy
    5.3.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    5.3.1.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
  5.3.2. Autonomic Neuropathy
    5.3.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    5.3.2.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
  5.3.3. Proximal Neuropathy
    5.3.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    5.3.3.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)
  5.3.4. Focal Neuropathy
    5.3.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    5.3.4.2. Regional breakdown estimates & forecasts, 2015-2025 (USD Billion)

CHAPTER 6. GLOBAL DIABETIC NEUROPATHY MARKET, BY REGIONAL ANALYSIS

6.1. Diabetic Neuropathy Market, Regional Market Snapshot (2015-2025)
6.2. North America Diabetic Neuropathy Market Snapshot
  6.2.1. U.S.
    6.2.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    6.2.1.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)
  6.2.2. Canada
    6.2.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    6.2.2.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)
6.3. Europe Diabetic Neuropathy Market Snapshot
  6.3.1. U.K.
    6.3.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    6.3.1.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)
  6.3.2. Germany
    6.3.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    6.3.2.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)
  6.3.3. France
    6.3.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    6.3.3.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)
  6.3.4. Rest of Europe
    6.3.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    6.3.4.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)
6.4. Asia Diabetic Neuropathy Market Snapshot
  6.4.1. China
    6.4.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    6.4.1.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)
  6.4.2. India
    6.4.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    6.4.2.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)
  6.4.3. Japan
    6.4.3.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    6.4.3.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)
  6.4.4. Rest of Asia Pacific
    6.4.4.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    6.4.4.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)
6.5. Latin America Diabetic Neuropathy Market Snapshot
  6.5.1. Brazil
    6.5.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    6.5.1.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)
  6.5.2. Mexico
    6.5.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    6.5.2.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)
6.6. Rest of The World
  6.6.1. South America
    6.6.1.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    6.6.1.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)
  6.6.2. Middle East and Africa
    6.6.2.1. Market estimates & forecasts, 2015-2025 (USD Billion)
    6.6.2.2. Types of Disorder breakdown estimates & forecasts, 2015-2025 (USD Billion)

CHAPTER 7. COMPETITIVE INTELLIGENCE

7.1. Company Market Share (Subject to Data Availability)
7.2. Top Market Strategies
7.3. Company Profiles
  7.3.1. Pfizer, Inc
    7.3.1.1. Overview
    7.3.1.2. Financial (Subject to Data Availability)
    7.3.1.3. Product Summary
    7.3.1.4. Recent Developments
  7.3.2. Johnson & Johnson
  7.3.3. Boehringer Ingelheim GmbH.
  7.3.4. NeuroMetrix, Inc.
  7.3.5. Eli Lilly and Company
  7.3.6. Astellas Pharma Inc
  7.3.7. GlaxoSmithKline plc.
  7.3.8. Lupin Limited
  7.3.9. Depomed, Inc.
  7.3.10. Glenmark Pharmaceuticals Ltd.
  7.3.11. Arbor Pharmaceuticals, LLC